uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face April 13, 2026, Deadline

Core Viewpoint - A securities fraud class action lawsuit has been filed against uniQure N.V. for misleading investors regarding its gene therapy drug AMT-130 during the specified Class Period [2][4]. Group 1: Lawsuit Details - The lawsuit, titled Scocco v. uniQure N.V., was filed in the United States District Court for the Southern District of New York [2]. - The Class Period for the lawsuit is defined as September 24, 2025, to October 31, 2025 [6]. - Investors have until April 13, 2026, to apply to serve as lead plaintiff in the class action [3][6]. Group 2: Allegations Against uniQure - The complaint alleges that uniQure made materially false and misleading statements regarding its Phase I/II clinical trials of AMT-130 and the timeline for its Biologics License Application (BLA) submission to the FDA [4][5]. - Specific allegations include that the design of the Pivotal Study was not fully approved by the FDA and that uniQure downplayed the likelihood of needing to delay its BLA timeline due to additional studies [5]. - The lawsuit claims that the statements made by uniQure lacked a reasonable basis, impacting investor decisions [5]. Group 3: Investor Actions - Investors who purchased uniQure shares during the Class Period are encouraged to contact Kessler Topaz Meltzer & Check, LLP for legal representation and recovery options [6][9]. - Investors can choose to file for lead plaintiff status or remain as absent class members without any obligation [6][8].